Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

BioGend Therapeutics Co., Ltd. (6733) Income Statement

BioGend Therapeutics Co., Ltd. Income Statement

Last quarter (Q2 2026), BioGend Therapeutics Co., Ltd.'s total revenue was NT$59.49M, an increase of 12.85% from the same quarter last year. In Q2, BioGend Therapeutics Co., Ltd.'s net income was NT$-23.92M. See BioGend Therapeutics Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.

Income Statement
Income StatementDec 25Dec 24Dec 23Dec 22Dec 21
NT$ 222.34MNT$ 167.65MNT$ 109.91MNT$ 31.45MNT$ 9.27M
NT$ 160.16MNT$ 130.51MNT$ 89.62MNT$ 22.78MNT$ 3.06M
NT$ 270.65MNT$ 252.77MNT$ 266.16MNT$ 241.99MNT$ 167.37M
Depreciation and AmortizationNT$ 49.77MNT$ 51.19MNT$ 55.02MNT$ 53.18MNT$ 28.19M
NT$ -60.73MNT$ -74.38MNT$ -113.94MNT$ -160.62MNT$ -104.71M
NT$ -110.50MNT$ -122.26MNT$ -176.54MNT$ -213.80MNT$ -144.25M
NT$ 6.88MNT$ -5.99MNT$ 7.32MNT$ 5.32MNT$ 20.04M
NT$ -103.61MNT$ -128.25MNT$ -169.22MNT$ -213.90MNT$ -144.27M
NT$ -84.61MNT$ -116.47MNT$ -156.32MNT$ -184.46MNT$ -138.49M
Per Share Metrics
Basic EPSNT$ -0.69NT$ -0.95NT$ -1.30NT$ -1.79NT$ -1.37
Diluted EPSNT$ -0.69NT$ -0.95NT$ -1.30NT$ -1.79NT$ -1.37
Weighted Average Shares Outstanding123.00M123.08M120.25M103.08M101.28M
Weighted Average Shares Outstanding (Diluted)123.00M123.08M120.28M103.08M101.28M

Currency in TWD

BioGend Therapeutics Co., Ltd. Earnings and Revenue History

-250M0250M500M-12000 %-8000 %-4000 %0 %EarningsProfit Margin2019202020212022202320242025RevenueEarningsProfit Margin